Mayne Pharma Group ( (AU:MYX) ) has provided an announcement.
UBS Group AG and its related corporate bodies have become substantial holders in Mayne Pharma Group Limited as of February 28, 2025, with a voting power of 6.32%. This acquisition of a significant shareholding stake by UBS could impact Mayne Pharma’s market positioning and influence future strategic decisions, potentially affecting stakeholders and the company’s operational dynamics.
More about Mayne Pharma Group
Mayne Pharma Group Limited is a pharmaceutical company that specializes in the development and manufacturing of branded and generic pharmaceutical products. The company focuses on delivering high-quality medications across various therapeutic areas to improve patient health outcomes.
YTD Price Performance: 52.43%
Average Trading Volume: 2,515
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $365.3M
See more insights into MYX stock on TipRanks’ Stock Analysis page.